The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Open accessAbstract
We analyzed the presenting features and survival in 1689 patients with multiple myeloma aged younger than 50 years compared with 8860 patients 50 years of age and older. Of the total 10 549 patients, 7765 received conventional therapy and 2784 received high-dose therapy. Young patients were more frequently male, had more favorable features such as low International Staging System (ISS) and Durie-Salmon stage as well as less frequently adverse prognostic factors including high C-reactive protein (CRP), low hemoglobin, increased serum creatinine, and poor performance status. Survival was significantly longer in young patients (median, 5.2 years vs 3.7 years; P < .001) both after conventional (median, 4.5 years vs 3.3 years; P < .001) or high-dose therapy (median, 7.5 years vs 5.7 years; P = .04). The 10-year survival rate was 19% after conventional therapy and 43% after high-dose therapy in young patients, and 8% and 29%, respectively, in older patients. Multivariate analysis revealed age as an independent risk factor during conventional therapy, but not after autologous transplantation. A total of 5 of the 10 independent risk factors identified for conventional therapy were also relevant for autologous transplantation. After adjusting for normal mortality, lower ISS stage and other favorable prognostic features seem to account for the significantly longer survival of young patients with multiple myeloma with age remaining a risk factor during conventional therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple myeloma presents with more favorable features and is associated with improved overall survival (OS) in patients <50 years old as compared with individuals >50.266”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [266]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationSEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447 · cited 1×
“8 mg/dL or more 7/33 (21) 312/1103 (28) 529/1872 (28) 251/732 (34) .”
Self-citationRegression models for relative survival
Dickman, P. W., Sloggett, A., Hills, M., & Hakulinen, T. (2004) · Statistics in Medicine · doi:10.1002/sim.1597 · Cited by 792
Multiple myeloma; a review of 26 cases.
Harnagel, E. E., Kleinberg, I., Kahlstrom, S. C., & Rhudy, F. V. (1957) · PubMed · Cited by 682
Cited by
Sonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C., Chng, W.-J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 928
Self-citationInternational Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Self-citationIs early-onset cancer an emerging global epidemic? Current evidence and future implications
Ugai, T., Sasamoto, N., Lee, H.-Y., Ando, M., Song, M., Tamimi, R. M., Kawachi, I., Campbell, P. T., Giovannucci, E. L., Weiderpass, E., et al. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00672-8 · Cited by 603
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358812 · Cited by 352
Self-citation
Metadata
- Authors
- Ludwig, H., Durie, B. G. M., Bolejack, V., Turesson, I., Kyle, R. A., Blade, J., Fonseca, R., Dimopoulos, M., Shimizu, K., San Miguel, J., Westin, J., Harousseau, J.-L., Beksac, M., Boccadoro, M., Palumbo, A., Barlogie, B., Shustik, C., Cavo, M., Greipp, P. R., Joshua, D., Attal, M., Sonneveld, P., & Crowley, J.
- Affiliations
- Wilhelminen Hospital (AT)
- Cedars-Sinai Medical Center (US)
- Cancer Research And Biostatistics (US)
- Department of Hematology, University Hospital, Malmö, Sweden;
- Mayo Clinic (US)
- Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Institut d' Investigacious Biomediques August Pi i Sunyer, Barcelona, Spain;
- Division of Hematology and Oncology, Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ;
- National and Kapodistrian University of Athens (GR)
- Department of Medicine, Nagoya City Midori General Hospital, Nagoya, Japan;
- University Hospital of Salamanca, Salamanca, Spain;
- Skåne University Hospital (SE)
- Centre Hospitalier Universitaire de Nantes (FR)
- Department of Microbiology and Clinical Microbiology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, Turkey;
- University of Turin (IT)
- University of Arkansas for Medical Sciences (US)
- McGill University (CA)
- Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy;
- Royal Prince Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Erasmus MC (NL)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-04-15
- Volume
- 111
- Issue
- 8
- Pages
- 4039-4047
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4259800
- OpenAlex
- W2137040543
- Cited by
- 230
- References
- 40
- Citations by year
- 2026: 1 · 2025: 13 · 2024: 11 · 2023: 21 · 2022: 11 · 2021: 9 · 2020: 14 · 2019: 22 · 2018: 9 · 2017: 14 · 2016: 18 · 2015: 13 · 2014: 12 · 2013: 15 · 2012: 9
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- multiple myeloma, young patients, age as risk factor, survival, prognostic factors, International Staging System, Durie-Salmon stage, autologous stem cell transplantation, high-dose therapy, conventional therapy, C-reactive protein
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, International Cooperation, Male, Middle Aged, Multiple Myeloma, Prognosis, Risk Factors, Multivariate Analysis, Survival Analysis, Age Distribution, Cytogenetic Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. https://app.cochat.ai/papers/10.1182/blood-2007-03-081018
- The paper
- Ludwig, H., Durie, B. G. M., Bolejack, V., Turesson, I., Kyle, R. A., Blade, J., Fonseca, R., Dimopoulos, M., Shimizu, K., San Miguel, J., Westin, J., Harousseau, J.-L., Beksac, M., Boccadoro, M., Palumbo, A., Barlogie, B., Shustik, C., Cavo, M., Greipp, P. R., . . . Crowley, J. (2008). Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. https://doi.org/10.1182/blood-2007-03-081018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.